Immunomedics secures patent for investigational cancer treatment
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Immunomedics Inc. secured patent coverage for its IMMU-140 cancer treatment in the U.S.
The protection will last until July 2033 and will cover the use of IMMU-140 in multiple cancer types, including melanoma, kidney or liver.
IMMU-140 is an investigational drug that is currently under development.
